Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lonapegsomatropin (Skytrofa) vs Mecasermin (Increlex)
An educational, source-based comparison of Lonapegsomatropin (Skytrofa) and Mecasermin (Increlex) — how each peptide works, what it's researched for, and what to know before going deeper.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
Lonapegsomatropin (Skytrofa) vs Mecasermin (Increlex) — Key differences
- Class: Lonapegsomatropin (Skytrofa) is classified as GH Analog · Endocrine, while Mecasermin (Increlex) is IGF-1 · Endocrine.
- Primary research focus: Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency; Mecasermin (Increlex) — severe primary igf-1 deficiency.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.